

China-Biotics, Inc. Received GMP Approval for its New Qingpu Production Facility

Shanghai, China, April 20, 2010 – **China-Biotics, Inc. ("China-Biotics", the "Company") (NASDAQ: CHBT)**, the leading developer, manufacturer and distributor of probiotics products in China, today announced that it has received the Good Manufacturing Process ("GMP") approval from the Shanghai Food and Drug Administration ("SHFDA") for its new production facility in Qingpu Industrial Park.

With this certificate, China-Biotics' new Qingpu facility is manufacturing all probiotic products under the nation's strict GMP standard. This certificate is valid through March 28, 2013 and is renewable. The Company's Qingpu facility features a 150 metric ton annual production capacity with production expected to reach a run rate of 75 metric tons by the end of 2010.

Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics, commented, "We are excited that our new state-of-the-art facility, featuring our own proprietary fermentation technologies and highly automated processing modules, has met the stringent requirements of the SFDA and it serves as a testament to our production management and quality control. GMP approval for probiotic products is one of the prerequisite metrics for a supplier to major dairy producers in China. As probiotics are increasingly used in yogurt and milk powder in China, we now look forward to ramping up our commercial production to meet the growing demand for probiotic products nationwide."

About China-Biotics

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company develops and produces its proprietary product portfolio including live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. In February 2010, China-Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit <http://www.chn-biotics.com>.

Safe Harbor Statement

The information in this release contains forward-looking statements which involve risks and uncertainties, including statements regarding the Company's capital needs, business strategy and expectations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, which may be identified by terminology such as "may," "should," "will," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "forecast," "project," or "continue," the negative of such terms or other comparable terminology. Readers should not rely on forward-looking statements as predictions of future events or results. Any or all of the Company's forward-looking statements may turn

out to be wrong. They can be affected by inaccurate assumptions, risks and uncertainties and other factors which could cause actual events or results to be materially different from those expressed or implied in the forward-looking statements. In evaluating these statements, readers should consider various factors, including the risks described in "Item 1A. Risk Factors" beginning on page 15 and elsewhere in the Company's 2009 Annual Report on Form 10-K. These factors may cause the Company's actual results to differ materially from any forward-looking statement. In addition, new factors emerge from time to time and it is not possible for the Company to predict all factors that may cause actual results to differ materially from those contained in any forward-looking statements. The Company disclaims any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this document, except as required by applicable law.

Contact:

Travis Cai
Chief Financial Officer
China-Biotics, Inc.
traviscai@chn-biotics.com

Kevin Theiss
Grayling
646-284-9409
kevin.theiss@grayling.com